Search Clinical Trials in the European Union

Duration
11-15 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 306 trials

Refractory Invasive Pulmonary Aspergillosis: Nebulized PC945

We are studying a new nebulized treatment, PC945, for patients with a tough-to-treat fungal infection. The goal is to see if it works better when combined with standard antifungal therapies.

Pulmonary Aspergillosis3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Rheumatoid Arthritis: Baricitinib and Anti-TNF Combination Study

We are investigating whether combining baricitinib with anti-TNF therapy helps patients with rheumatoid arthritis who haven't responded to other treatments. The study will also look at safety and how well patients can reduce their steroid use.

Rheumatoid Arthritis6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Alcohol-Related Liver Disease: GSK4532990 Study

We are investigating a new medication, GSK4532990, for adults with alcohol-related liver disease. The study aims to see if it is safe and effective compared to a placebo.

Alcoholic Liver Disease1-2 yearsEfficacy phase (II)11-15 visitsHepatologyInternal Medicine

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Type 2 Diabetes: Dapansutrile Study

We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDiabetologyEndocrinology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Colorectal Cancer: STC-1010 Immunotherapy

We are studying a new immunotherapy for patients with advanced colorectal cancer that cannot be surgically removed. The trial aims to evaluate its safety and effectiveness alongside standard treatment options.

Unresectable Locally Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Prostate Cancer: Re-treatment with [177Lu]Lu-PSMA

We are studying the effects of re-treating men with metastatic castration-resistant prostate cancer using [177Lu]Lu-PSMA. This trial aims to see if this treatment can help improve survival and quality of life.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine